Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Epigenomics
; 14(22): 1449-1464, 2022 11.
Article
em En
| MEDLINE
| ID: mdl-36601794
EZH2 is a histone methyltransferase whose high expression is associated with a poor prognosis in various solid tumors. It is considered a target for cancer treatment. However, EZH2 inhibitors as monotherapy have shown disappointing efficacy in most solid tumors. This review summarizes the strategies of combining EZH2 inhibitors with other treatment regimens and their associated molecular mechanisms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
Proteína Potenciadora do Homólogo 2 de Zeste
Limite:
Humans
Idioma:
En
Revista:
Epigenomics
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China
País de publicação:
Reino Unido